New eye drops aim to ease dry eye symptoms for millions
NCT ID NCT07457021
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will test perfluorohexyloctane eye drops, the only approved drug in China for dry eye disease related to meibomian gland dysfunction. Researchers plan to enroll 2000 adults and track their symptoms, eye health, and any side effects over 12 weeks. The goal is to see how well the drops work in real-world conditions, alone or with other treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- perfluorohexyloctane eye drops
- What this could lead to
- If successful, this could confirm that perfluorohexyloctane eye drops are a safe and effective option for treating dry eye symptoms in everyday medical practice.
- What could go wrong
- This is an observational real-world study, not a controlled trial, so results may be less definitive. Side effects or lack of benefit are possible, and the study has not yet started recruiting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRY EYE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Xiamen Eye Center Affiliated to Xiamen University
Xiamen, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Dry eye gel may sharpen cataract surgery results
- New eye drops could bring relief to millions with chronic dry eye
- Could stem cell eye drops soothe dry eyes?
- Second plug may boost dry eye comfort
- New AI reads eye scans to diagnose dry eye instantly
- Popular diabetes drugs may ease dry eye, study suggests